NewsBenzinga굿알엑스, 제약사 직접 매출 2,977만 3천 달러 과소계상으로 2026년 1분기 및 2분기 재무제표 신뢰 불가 발표···중대한 약점 예상 굿알엑스, 제약사 직접 매출 2,977만 3천 달러 과소계상으로 2026년 1분기 및 2분기 재무제표 신뢰 불가 발표···중대한 약점 예상 Benzinga 2026.11.02 21:58 (GMT+0) Open on Benzinga Other news Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds